All In Biotech

Free tool

FAERS Monitor: Nextstellis

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214154 or its brand name (Nextstellis, Drospirenone, Estetrol). Reports on generic versions are filed under their own applications.

Reports

296

Serious

102

34% of reports

Hospitalization

29

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • intermenstrual bleeding26
  • heavy menstrual bleeding21
  • headache16
  • drug ineffective15
  • dizziness13
  • mood swings12
  • off label use12
  • nausea11
  • product use in unapproved indication11
  • migraine10
  • suicidal ideation10
  • weight increased10
  • depression9
  • menstruation irregular9
  • alopecia8

Reports by year received

View as table
YearReports
20217
202275
202364
202428
202545
202677

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,863 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intermenstrual bleedingSignal26332.1229.98,219
heavy menstrual bleedingSignal21166.2110.03,280
mood swingsSignal1226.815.4273
menstruation irregularSignal923.912.6175
suicidal ideationSignal107.84.253
migraineSignal107.44.050
weight increasedSignal103.21.713
product use in unapproved indicationSignal113.21.814
alopeciaSignal82.91.58
depressionSignal92.81.59
dizziness131.91.14
headache161.81.15
nausea111.00.60
off label use121.00.60
drug ineffective150.80.51

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.